Vertex at peak of cystic fibrosis market for years to come

2 September 2021
lab_biotech_test_big

Research from industry analyst GlobalData underscores the dominance of two players in the cystic fibrosis (CF) space - Vertex Pharmaceuticals (Nasdaq: VRTX) and AbbVie (NYSE: ABBV).

The treatment landscape has been reformed in recent years by the development of disease-modifying options known as CFTR modulators, a trend that is likely to continue.

The cystic fibrosis market is expected to grow from $8.2 billion in 2020 to $12.7 billion in 2030 in the seven major markets (7MM) at a compound annual growth rate (CAGR) of 4.5%, according to GlobalData.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical